| [1] |
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer(ABC 5)[J]. Ann Oncol, 2020, 31(12):1623-1649.
|
| [2] |
Cardoso F, Spence D, Mertz S, et al. Global analysis of advanced/metastatic breast cancer: decade report (2005-2015)[J]. Breast, 2018, 39:131-138.
|
| [3] |
Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?[J]. J Natl Cancer Inst, 2010, 102(7):456-463.
|
| [4] |
林雪芳, 林添钰, 丘建燊, 等. 肺占位穿刺基于CT评估肺出血风险的临床研究[J]. 临床肺科杂志, 2022, 27(3):370-375.
|
| [5] |
Matsuura K, Itamoto T, Noma M, et al. Significance of lung biopsy for the definitive diagnosis of lung nodules in breast cancer patients[J]. Mol Clin Oncol, 2018, 8(2):250-256.
|
| [6] |
Beji H, Pilleul F, Picard R, et al. Percutaneous cryoablation of breast tumours in patients with stable metastatic breast cancer: safety, feasibility and efficacy[J]. Br J Radiol, 2018, 91(1083):20170500.
|
| [7] |
Brkljacic B, Cikara I, Ivanac G, et al. Ultrasound-guided bipolar radiofrequency ablation of breast cancer in in-operable patients: a pilot study[J]. Ultraschall Med, 2010, 31(2):156-162.
|
| [8] |
杨小青, 秦春新, 周少杰. 局部晚期乳腺癌的微波消融治疗[J]. 局解手术学杂志, 2018, 27(11):845-847.
|
| [9] |
Neal RE 2nd, Singh R, Hatcher HC, et al. Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode[J]. Breast Cancer Res Treat, 2010, 123(1):295-301.
|
| [10] |
Roknsharifi S, Wattamwar K, Fishman MDC, et al. Image-guided microinvasive percutaneous treatment of breast lesions: where do we stand?[J]. Radiographics, 2021, 41(4):945-966.
|
| [11] |
Ma J, Song J, Chen H, et al. Intra-arterial interventional therapy for inoperable local advanced breast cancer: a retrospective study[J]. Oncol Lett, 2018, 15(2):1955-1962.
|
| [12] |
Wang X, Gan C, Li H, et al. Main complications and results of treatment with intra-arterial infusion chemotherapy through the subclavian and thoracic arteries for locally advanced breast cancer[J]. Mol Clin Oncol, 2013, 1(4):745-748.
|
| [13] |
许彪, 庄亚强, 刘惕生, 等. 多支超选择性动脉化疗联合手术治疗中晚期乳腺癌[J]. 实用放射学杂志, 2011, 27(6):925-928.
|
| [14] |
周韬, 庄亚强, 许彪, 等. DSA下多支超选择性动脉灌注化疗联合手术治疗中晚期乳腺癌的临床疗效分析[J]. 现代肿瘤医学, 2012, 20(7):1363-1366.
|
| [15] |
Guirguis MS, Checka C, Adrada BE, et al. Bracketing with multiple radioactive seeds to achieve negative margins in breast conservation surgery: multiple seeds in breast surgery[J]. Clin Breast Cancer, 2022, 22(2):e158-e166.
|
| [16] |
de Campos TP, Nogueira LB, Trindade B, et al. Dosime-tric intercomparison of permanent Ho-166 seed′s implants and HDR Ir-192 brachytherapy in breast cancer[J]. Rep Pract Oncol Radiother, 2016, 21(3):240-249.
|
| [17] |
Barral M, Auperin A, Hakime A, et al. Percutaneous thermal ablation of breast cancer metastases in oligometastatic patients[J]. Cardiovasc Intervent Radiol, 2016, 39(6):885-893.
|
| [18] |
Kent CL, McDuff SGR, Salama JK. Oligometastatic breast cancer: where are we now and where are we headed?—a narrative review[J]. Ann Palliat Med, 2021, 10(5):5954-5968.
|
| [19] |
Kwapisz D. Oligometastatic breast cancer[J]. Breast Cancer, 2019, 26(2):138-146.
|
| [20] |
Ridouani F, Solomon SB, Bryce Y, et al. Predictors of progression-free survival and local tumor control after percutaneous thermal ablation of oligometastatic breast cancer: retrospective study[J]. J Vasc Interv Radiol, 2020, 31(8):1201-1209.
|
| [21] |
AlSendi M, O′Reilly D, Zeidan YH, et al. Oligometastatic breast cancer: are we there yet?[J]. Int J Cancer, 2021, 149(8):1520-1528.
|
| [22] |
Kobayashi T, Ichiba T, Sakuyama T, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review[J]. Breast Cancer, 2012, 19(3):218-237.
|
| [23] |
Tewes M, Peis MW, Bogner S, et al. Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: effcacy, safety and prognostic parameters[J]. J Cancer Res Clin Oncol, 2017, 143(10):2131-2141.
|
| [24] |
Aarts BM, Klompenhouwer EG, Dresen RC, et al. Intra-arterial mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival[J]. Breast Cancer Res Treat, 2019, 176(3):597-605.
|
| [25] |
Firmino F, Villela-Castro DL, Santos JD, et al. Topical management of bleeding from malignant wounds caused by breast cancer: a systematic review[J]. J Pain Symptom Manage, 2021, 61(6):1278-1286.
|
| [26] |
Firmino F, Santos J, Meira KC, et al. Regenerated oxidised cellulose versus calcium alginate in controlling bleeding from malignant breast cancer wounds: randomised control trial study protocol[J]. J Wound Care, 2020, 29(1):52-60.
|
| [27] |
Kitayama K, Ozaki M, Ninoi T, et al. A case of effective endovascular treatment for recurrent bleeding from advanced breast cancer[J]. Gan To Kagaku Ryoho, 2020, 47(13):2394-2396.
|
| [28] |
Ledys F, Kalfeist L, Galland L, et al. Therapeutic associa-tions comprising anti-PD-1/PD-L1 in breast cancer: clinical challenges and perspectives[J]. Cancers (Basel), 2021, 13(23):5999.
|
| [29] |
Guo X, Du F, Liu Q, et al. Immunological effect of irreversible electroporation on hepatocellular carcinoma[J]. BMC Cancer, 2021, 21(1):443.
|
| [30] |
Li J, Liu F, Gupta S, et al. Interventional nanotheranostics of pancreatic ductal adenocarcinoma[J]. Theranostics, 2016, 15, 6(9):1393-1402.
|
| [31] |
陈艳军, 程冰冰, 郜宇, 等. 纳米刀消融治疗局部进展期胰腺癌的免疫机制研究[J]. 医药论坛杂志, 2021, 42(4):1-6,11.
|
| [32] |
Ringel-Scaia VM, Beitel-White N, Lorenzo MF, et al. High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity[J]. EBioMedicine, 2019, 44:112-125.
|
| [33] |
Shao Q, O′Flanagan S, Lam T, et al. Engineering T cell response to cancer antigens by choice of focal therapeutic conditions[J]. Int J Hyperthermia, 2019, 36(1):130-138.
|
| [34] |
He C, Huang X, Zhang Y, et al. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer[J]. Clin Transl Med, 2020, 10(2):e39.
|
| [35] |
Dai Z, Wang Z, Lei K, et al. Irreversible electroporation induces CD8+ T cell immune response against post-ablation hepatocellular carcinoma growth[J]. Cancer Lett, 2021, 503:1-10.
|
| [36] |
Scheffer HJ, Stam AGM, Geboers B, et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation[J]. Oncoimmunology, 2019, 8(11):1652532.
|
| [37] |
Beitel-White N, Martin RCG, Li Y, et al. Real-time prediction of patient immune cell modulation during irreversible electroporation therapy[J]. Sci Rep, 2019, 9(1):17739.
|
| [38] |
Holgado E, Perez-Garcia J, Gion M, et al. Is there a role for immunotherapy in HER2-positive breast cancer?[J]. NPJ Breast Cancer, 2018, 4:21.
|
| [39] |
Zhao J, Wen X, Tian L, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer[J]. Nat Commun, 2019, 10(1):899.
|
)
